Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.
But other small biotechs are more advanced and still hope to play a role in the pandemic.
Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.
Glaxo’s anti-PD-1 MAb might not have a market niche to itself for long, while a separate trial could help Keytruda double its adjuvant melanoma potential.
A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
But is there room for another antibody, given lacklustre sales and Regeneron’s dominance?